Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (533)	12/10/2001 9:49:59 AM
From: tuck	Respond to of 1005

IPO market unfriendly indeed. I note the underwriters are not even close to putting numbers into the Bruker AXS S-1. Well, that at least reduces the research burdens here at BLUE HP . . . >>MOUNTAIN VIEW, Calif., Dec. 10 /PRNewswire/ -- Caliper Technologies Corp. (Nasdaq: CALP - news) and Wako Pure Chemical Industries, Ltd. of Japan have formed an exclusive agreement providing Wako with rights to distribute the Caliper 250 High Throughput Screening (HTS) system and chips in Japan. Caliper Technologies develops and manufactures LabChip® systems and sells them in the U.S. through the company's own direct domestic sales organization. The agreement with Wako represents Caliper's first HTS product marketing endeavor in Japan. The Caliper 250 HTS system miniaturizes, integrates and automates high-throughput screening, the process of testing each component of large chemical compound libraries to discover and characterize compounds with specific biochemical activities. Pharmaceutical companies use high-throughput screening assays to uncover compounds of potential therapeutic value. A single high-throughput-screening project might require critical laboratory analysis of hundreds of thousands of individual chemical compounds. By performing high-throughput screening on a small chip as part of an automated workflow, the Caliper 250 HTS system speeds up the assay development process, improves data quality and reproducibility, and reduces reagent and sample usage. Through well-established relationships with leading Japanese pharmaceutical companies, Wako offers market access, leadership and reach to promote Caliper's HTS systems in Japan. Wako is a major supplier of specialty chemicals, clinical diagnostics, and biological products for Japanese biotech research. For more information, please visit Wako's web site at wako-chem.co.jp .<< snip Cheers, Tuck

To: keokalani'nui who wrote (533)	12/11/2001 2:17:00 PM
From: tuck	Read Replies (1) \| Respond to of 1005

Permit me a correction on the impending Bruker AXS IPO. In the latest S-1/A, the underwriters have given a range: 9 million shares offered for $8 - $10 per share, with overallotment option of 1.35 million shares. 53,532,261 shares will be outstanding unless the deal prices below the range, in which case more shares (up to 7.4+ million) could be issued. Guess they feel they need a certain amount. CIBC leading. Cheers, Tuck

To: keokalani'nui who wrote (533)	12/14/2001 9:34:17 AM
From: tuck	Respond to of 1005

A fresh victim! >>MADISON, Wis.--(BUSINESS WIRE)--Dec. 14, 2001--Bruker AXS Inc. (NASDAQ: BAXS - news) today announced that it has priced its initial public offering of 9,000,000 shares of common stock at a price of $6.50 per share. The net proceeds from this offering are $52,905,000, not including the underwriters' over-allotment. The shares will commence trading today on the NASDAQ National Market under the symbol ``BAXS''. The company anticipates using net proceeds from the offering for general corporate purposes, including research and development, expansion of sales and marketing capabilities, working capital, strategic acquisitions, facilities expansion and repayment of long-term and short-term debt. UBS Warburg LLC is bookrunning manager and, along with Thomas Weisel Partners LLC, co-lead manager of the offering. CIBC World Markets, SG Cowen and Robert W. Baird & Co. are the co-managers. Bruker AXS has granted the underwriters the option to purchase an aggregate of 1,350,000 additional shares to cover over-allotments, if any. A copy of the final prospectus may be obtained from the offices of UBS Warburg LLC, 299 Park Avenue, 41st Floor, New York, NY 10171. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the common stock of Bruker AXS, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Bruker AXS is a leading worldwide developer and provider of advanced X-ray systems which provide solutions for molecular and elemental analysis by X-ray crystallography, X-ray diffraction and X-ray fluorescence. Its integrated systems, which have particular application in the drug discovery and materials science fields, provide customers with high throughout capabilities to determine the structure of specific molecules, such as proteins, and to characterize and determine the composition of materials. Bruker AXS' substantial investment in research and development allows it to design, manufacture and market technologically innovative, integrated solutions to meet the rapidly growing needs of a diverse customer base, including biotechnology and pharmaceutical companies, semiconductor companies, raw materials manufacturers, chemical companies, academic institutions and other businesses involved in materials analysis. -------------------------------------------------------------------------------- Contact: Bruker AXS Inc. John Bourke, 608/276-3833 Jbourke@bruker-axs.com<< Putting it in the WatchList. Cheers, Tuck

To: keokalani'nui who wrote (533)	12/14/2001 12:49:43 PM
From: tuck	Read Replies (1) \| Respond to of 1005

And another one, in fact the very one you mention, Wilder. BLUE HP's cup runneth over! >>BOTHELL, Wash.--(BW HealthWire)--Dec. 14, 2001--Northwest Biotherapeutics, Inc. (Nasdaq:NWBT - news) today announced that it commenced its initial public offering of 4,000,000 shares of its common stock at a price of $5 per share. The public offering was led by C.E. Unterberg, Towbin, with Fahnestock & Co. Inc. and Roth Capital Partners, LLC as co-managers. All of the shares were sold by the Company. The Company has granted the underwriters an option to purchase an additional 600,000 shares solely to cover over-allotments, if any. The Company's common stock will be traded on the Nasdaq National Market under the symbol ``NWBT.'' Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. The Company combines its expertise in dendritic cell biology, immunology and antigen discovery with its proprietary technologies to develop cancer therapies. The Company's development efforts are based on two versatile product development programs - DCVax(TM), a dendritic cell-based immunotherapy platform and HuRx(TM), a fully human monoclonal antibody platform. The Company's lead DCVax product candidate, DCVAX-Prostate, is a prostate cancer treatment for which the Company is commencing a Phase III clinical trial. HuRx(TM) is a fully human monoclonal antibody program that is being co-developed with Medarex, Inc. The Company's lead HuRx(TM) product candidate, HuRx-Prostate, is currently being manufactured for anticipated Phase I clinical trials. Copies of the prospectus relating to the underwritten public offering may be obtained from C.E. Unterberg, Towbin, 350 Madison Avenue, New York, New York 10017, Attn: Prospectus Department. nwbio.com -------------------------------------------------------------------------------- Contact: Northwest Biotherapeutics, Inc., Bothell Mary Royals, 202/778-1021 mroyals@apcoassoc.com<< snip Cheers, Tuck